BR112014008314A2 - composições para tratamento de olho seco - Google Patents

composições para tratamento de olho seco

Info

Publication number
BR112014008314A2
BR112014008314A2 BR112014008314A BR112014008314A BR112014008314A2 BR 112014008314 A2 BR112014008314 A2 BR 112014008314A2 BR 112014008314 A BR112014008314 A BR 112014008314A BR 112014008314 A BR112014008314 A BR 112014008314A BR 112014008314 A2 BR112014008314 A2 BR 112014008314A2
Authority
BR
Brazil
Prior art keywords
dry eye
care compositions
eye care
animals
treat
Prior art date
Application number
BR112014008314A
Other languages
English (en)
Other versions
BR112014008314B1 (pt
Inventor
G Vehige Joseph
A Simmons Peter
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47040830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014008314(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014008314A2 publication Critical patent/BR112014008314A2/pt
Publication of BR112014008314B1 publication Critical patent/BR112014008314B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

abstract the present invention relates to ophthalmic compositions and methods useful to treat dry eye, or to diagnose, cure, mitigate, treat, or prevent dry eye syndrome in man or other animals. ______________ tradução do resumo resumo patente de invenção: "composições para tratamento de olho seco". a presente invenção refere-se à composições oftálmicas e métodos úteis para tratar olho seco ou para diagnosticar, curar, aliviar, tratar ou prevenir síndrome do olho seco em seres humanos ou outros animais.
BR112014008314-2A 2011-10-06 2012-10-05 Composição oftálmica e seu uso BR112014008314B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544151P 2011-10-06 2011-10-06
US61/544,151 2011-10-06
PCT/US2012/058893 WO2013052760A1 (en) 2011-10-06 2012-10-05 Compositions for the treatment of dry eye

Publications (2)

Publication Number Publication Date
BR112014008314A2 true BR112014008314A2 (pt) 2017-04-11
BR112014008314B1 BR112014008314B1 (pt) 2022-04-05

Family

ID=47040830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008314-2A BR112014008314B1 (pt) 2011-10-06 2012-10-05 Composição oftálmica e seu uso

Country Status (17)

Country Link
US (7) US8957048B2 (pt)
EP (1) EP2765987A1 (pt)
JP (1) JP6209163B2 (pt)
CN (1) CN103974694A (pt)
AU (1) AU2012318556B2 (pt)
BR (1) BR112014008314B1 (pt)
CA (1) CA2851398C (pt)
CL (1) CL2014000863A1 (pt)
HK (1) HK1201042A1 (pt)
IL (1) IL231970A (pt)
MX (1) MX2014004203A (pt)
MY (1) MY169328A (pt)
RU (1) RU2651046C2 (pt)
SG (1) SG11201401323PA (pt)
TW (1) TWI642432B (pt)
WO (1) WO2013052760A1 (pt)
ZA (1) ZA201404121B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
EP3981387A1 (en) * 2011-12-07 2022-04-13 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
US20140377210A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Artificial tear compositions
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
US10624781B2 (en) 2015-01-12 2020-04-21 Kedalion Therapeutics, Inc. Micro-droplet delivery device and methods
JP2018515153A (ja) 2015-04-10 2018-06-14 ケダリオン セラピューティックス，インコーポレイテッド 交換式アンプルを備えた圧電式ディスペンサ
CN105311042B (zh) * 2015-09-07 2019-04-12 广州国宇医药科技有限公司 一种糖醇组合物在制备治疗干眼症的药物中的应用
WO2017116826A1 (en) * 2015-12-28 2017-07-06 Indiana University Research And Technology Corporation Identification of contact lens wearers predisposed to contact lens discomfort
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
GB201618175D0 (en) * 2016-10-27 2016-12-14 Warneford Healthcare Ltd Pharmaceutical compositions
KR20230107693A (ko) 2017-01-20 2023-07-17 노파르티스 아게 압전 유체 분배기
CN114376961A (zh) * 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
JP7150282B2 (ja) * 2017-09-14 2022-10-11 協同乳業株式会社 涙液分泌能・涙液安定性を改善するための飲食品または製剤
CN111712219A (zh) 2017-12-08 2020-09-25 科达莱昂治疗公司 流体递送对准系统
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
BR112022020948A2 (pt) 2020-04-17 2023-04-11 Kedallion Therapeutics Inc Sistema de distribuição livre de conservantes hidrodinamicamente atuado
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2022103775A1 (en) 2020-11-12 2022-05-19 Singletto Inc. Microbial disinfection for personal protection equipment
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
CN114533582B (zh) * 2022-02-25 2023-05-09 北京协和生物工程研究所有限公司 一种包含多种渗透压保护剂的眼周用组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Ocular cyclosporin composition
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
JPH0723302B1 (pt) 1989-08-03 1995-03-15
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
CN1160346A (zh) 1994-09-14 1997-09-24 大正制药株式会社 用于修复角膜损伤的滴眼液
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
DE19859910C2 (de) 1998-12-23 2001-03-22 Ratiopharm Gmbh Orales Arzneimittel
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
AU781975B2 (en) 2000-09-14 2005-06-23 Hayashibara Co., Ltd Pharmaceutical composition for ophthalmic use
CA2428985C (en) 2000-11-08 2011-05-24 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
WO2004084877A1 (ja) 2003-03-26 2004-10-07 Menicon Co., Ltd. 眼科用組成物
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CA2679448A1 (en) * 2007-02-28 2008-09-04 Aciex, Inc. Methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
CA2741288A1 (en) 2008-10-20 2010-04-29 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
AU2010256652B2 (en) * 2009-06-05 2015-11-26 Allergan, Inc. Artificial tears and therapeutic uses
US8613957B2 (en) 2009-10-07 2013-12-24 Kerecis Ehf Scaffold material for wound care and/or other tissue healing applications
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
EP3981387A1 (en) * 2011-12-07 2022-04-13 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Also Published As

Publication number Publication date
IL231970A0 (en) 2014-05-28
US20190247419A1 (en) 2019-08-15
AU2012318556B2 (en) 2017-10-26
JP2014528452A (ja) 2014-10-27
US8957048B2 (en) 2015-02-17
US20140242022A1 (en) 2014-08-28
US20150196582A1 (en) 2015-07-16
MY169328A (en) 2019-03-21
CN103974694A (zh) 2014-08-06
RU2014122945A (ru) 2015-12-20
US10105386B2 (en) 2018-10-23
CA2851398C (en) 2019-11-05
CA2851398A1 (en) 2013-04-11
ZA201404121B (en) 2016-07-27
EP2765987A1 (en) 2014-08-20
US20240122963A1 (en) 2024-04-18
NZ625799A (en) 2016-09-30
TWI642432B (zh) 2018-12-01
AU2012318556A1 (en) 2014-07-31
MX2014004203A (es) 2014-10-17
CN108175778A (zh) 2018-06-19
TW201316984A (zh) 2013-05-01
BR112014008314B1 (pt) 2022-04-05
US20130090308A1 (en) 2013-04-11
WO2013052760A1 (en) 2013-04-11
HK1201042A1 (en) 2015-08-21
SG11201401323PA (en) 2014-08-28
US20210000859A1 (en) 2021-01-07
CL2014000863A1 (es) 2014-08-29
IL231970A (en) 2016-12-29
US20220096523A1 (en) 2022-03-31
JP6209163B2 (ja) 2017-10-04
RU2651046C2 (ru) 2018-04-18

Similar Documents

Publication Publication Date Title
BR112014008314A2 (pt) composições para tratamento de olho seco
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112014010803A2 (pt) método de tratamento
BR112017008093A2 (pt) processos para tratamento de doenças oculares
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112015006055A2 (pt) composições e métodos para o tratamento e prevenção de lesão tecidual e doença
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112015026258A2 (pt) composições e agentes terapêuticos e imunomoduladores, e usos dos mesmos
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
BR112013018918A2 (pt) composições de nanopartículas
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015007758A2 (pt) dispositivo para um tratamento médico de uma esclera, método para tratar a esclera em um sujeito e método para tratar uma alteração patológica ou doença do olho.
WO2014186453A3 (en) Apparatus and method for administering a medical device prescription
BR112013028435A2 (pt) composição para aplicação transdérmica
BR112013025493A2 (pt) composição aquosa administrável de maneira tópica a um olho humano ou animal, método para tratar uma afecção que envolve deficiências em lágrimas naturais no olho humano ou animal, composição para aplicação tópica no tratamento de um distúrbio ou afecção ocular do olho humano ou animal, método para tratar um distúrbio ou afecção ocular do olho humano ou animal, composição para uso no tratamento de dor associada ao olho humano ou animal e método para alívio da dor no olho humano ou animal ou próximo ao mesmo
BR112015029611A2 (pt) composições para uso em ruptura de cartilagem
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
BR112014009866A2 (pt) formulações de anticorpos e métodos
BR112013018919A2 (pt) composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2012, OBSERVADAS AS CONDICOES LEGAIS.